Skip to content
GAIA-BTAgentic TechBio
TRY NOW (opens in new tab)
CompanyPartnersNewsCareersContact Us
TRY NOW (opens in new tab)
Global AI Agents for Bio Technology

The bottleneck isn't the hypothesis.
It's the validation after.

One ecosystem, one knowledge graph, one closed loop from hypothesis to validation.

See It Live ↗
Diagram of GAIA-BT's ecosystemGAIA-Phil, the agentic core, sits at the center of the K-GEM OS, connected to six partner types: University (Research · validation); Research Institute (Core tech · KG); Clinics / Hospital (Real patient biology); Biotechs (Assets · modalities); Pharmas (Clinical · scale-up); Government/Regulatory (Regulation · approvals).
Platform & Engine

Two Products,
Live at gaiabt.ai

K-GEM connects the ecosystem. GAIA-Phil is the intelligence that drives it.

K-GEM unified OS diagramA central K-GEM cell surrounded by six partner types — University, Research Institute, Clinics and Hospitals, Biotechs, Pharmas, and Government and Regulatory bodies — arranged as one honeycomb cluster.K-GEMUNIFIED OS
Unified OS

K-GEM™

The unified OS connecting universities, institutes, hospitals, biotechs, and pharmas into one open ecosystem.

Learn more
GAIA-Phil agentic core visualA field of specialist AI agent signals rising and converging into one coherent peak, representing GAIA-Phil, the agentic core.
Agentic Core · Orchestrator

GAIA-Phil™

The engine inside K-GEM™ — specialist AI agents orchestrated around one knowledge graph, closing the loop from hypothesis to validation.

Learn more
NEWS

What's new

24 JUN 2026Client

GAIA-BT to Lead "AI Optimization" of Cyron Therapeutics' Cancer Drug Candidates

GAIA-BT signed a research and development contract with Cyron Therapeutics for the optimization of anticancer therapeutic drug candidates, using the Optimization Agent of its K-GEM™ platform.

Read more
20 MAY 2026PartnershipGAIA-BT Signs Letter of Intent with Prosilico for AI-Based Drug Discovery Collaboration20 MAY 2026PartnershipGAIA-BT Signs MOU with Korea Institute of Toxicology for Joint R&D19 MAY 2026PartnershipGAIA-BT Signs Letter of Intent with ProEn Therapeutics for Joint R&D18 MAY 2026PartnershipGAIA-BT Signs Letter of Intent with Evidentia Labs for AI-Based Drug Discovery Collaboration15 MAY 2026Awards & GrantsGAIA-BT, GBSA-Certified Gyeonggi AI Membership CompanyAll news

Questions?

Contact us →